-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data

Benzinga·08/27/2026 06:25:22
Listen to the news
  • Submission supported by data from Phase 3 pivotal AFFIRM study
  • If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV) induction